JP2023036901A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023036901A5 JP2023036901A5 JP2022211549A JP2022211549A JP2023036901A5 JP 2023036901 A5 JP2023036901 A5 JP 2023036901A5 JP 2022211549 A JP2022211549 A JP 2022211549A JP 2022211549 A JP2022211549 A JP 2022211549A JP 2023036901 A5 JP2023036901 A5 JP 2023036901A5
- Authority
- JP
- Japan
- Prior art keywords
- coating
- sustained release
- antibody
- weight
- dosage form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000011248 coating agent Substances 0.000 claims 27
- 238000000576 coating method Methods 0.000 claims 27
- 238000000034 method Methods 0.000 claims 17
- 239000012634 fragment Substances 0.000 claims 15
- 238000013268 sustained release Methods 0.000 claims 14
- 239000012730 sustained-release form Substances 0.000 claims 14
- 239000007909 solid dosage form Substances 0.000 claims 10
- 239000000243 solution Substances 0.000 claims 10
- 239000013543 active substance Substances 0.000 claims 8
- 239000011230 binding agent Substances 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 7
- 229940079593 drug Drugs 0.000 claims 7
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims 6
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims 5
- 239000007788 liquid Substances 0.000 claims 5
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims 5
- 229920000642 polymer Polymers 0.000 claims 4
- 229920002845 Poly(methacrylic acid) Polymers 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 238000004581 coalescence Methods 0.000 claims 3
- 239000003623 enhancer Substances 0.000 claims 3
- 238000005507 spraying Methods 0.000 claims 3
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 2
- 102000013462 Interleukin-12 Human genes 0.000 claims 2
- 108010065805 Interleukin-12 Proteins 0.000 claims 2
- 102000003816 Interleukin-13 Human genes 0.000 claims 2
- 108090000176 Interleukin-13 Proteins 0.000 claims 2
- 102000013264 Interleukin-23 Human genes 0.000 claims 2
- 108010065637 Interleukin-23 Proteins 0.000 claims 2
- 102000004889 Interleukin-6 Human genes 0.000 claims 2
- 108090001005 Interleukin-6 Proteins 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- TYVWBCMQECJNSK-UHFFFAOYSA-N [2-methyl-3-(2-methylprop-2-enoyloxy)butan-2-yl]azanium;chloride Chemical compound [Cl-].CC([NH3+])(C)C(C)OC(=O)C(C)=C TYVWBCMQECJNSK-UHFFFAOYSA-N 0.000 claims 2
- 239000012190 activator Substances 0.000 claims 2
- 230000003111 delayed effect Effects 0.000 claims 2
- 238000001035 drying Methods 0.000 claims 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 2
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims 2
- 229940117681 interleukin-12 Drugs 0.000 claims 2
- 229940124829 interleukin-23 Drugs 0.000 claims 2
- 229940100601 interleukin-6 Drugs 0.000 claims 2
- 229920000609 methyl cellulose Polymers 0.000 claims 2
- 239000001923 methylcellulose Substances 0.000 claims 2
- 239000004014 plasticizer Substances 0.000 claims 2
- -1 poly(vinyl alcohol) Polymers 0.000 claims 2
- 229920005596 polymer binder Polymers 0.000 claims 2
- 239000002491 polymer binding agent Substances 0.000 claims 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- FEBUJFMRSBAMES-UHFFFAOYSA-N 2-[(2-{[3,5-dihydroxy-2-(hydroxymethyl)-6-phosphanyloxan-4-yl]oxy}-3,5-dihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-4-yl)oxy]-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl phosphinite Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(OC2C(C(OP)C(O)C(CO)O2)O)C(O)C(OC2C(C(CO)OC(P)C2O)O)O1 FEBUJFMRSBAMES-UHFFFAOYSA-N 0.000 claims 1
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 claims 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 1
- 229920000945 Amylopectin Polymers 0.000 claims 1
- 229920000856 Amylose Polymers 0.000 claims 1
- 239000001904 Arabinogalactan Substances 0.000 claims 1
- 229920000189 Arabinogalactan Polymers 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 claims 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims 1
- 229920002101 Chitin Polymers 0.000 claims 1
- 229920001661 Chitosan Polymers 0.000 claims 1
- 229920001287 Chondroitin sulfate Polymers 0.000 claims 1
- 229920000858 Cyclodextrin Polymers 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- 239000001856 Ethyl cellulose Substances 0.000 claims 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 1
- 229920003143 Eudragit® FS 30 D Polymers 0.000 claims 1
- 229920003139 Eudragit® L 100 Polymers 0.000 claims 1
- 229920003135 Eudragit® L 100-55 Polymers 0.000 claims 1
- 229920003138 Eudragit® L 30 D-55 Polymers 0.000 claims 1
- 229920003141 Eudragit® S 100 Polymers 0.000 claims 1
- 229920003142 Eudragit® S 12,5 Polymers 0.000 claims 1
- 229920003134 Eudragit® polymer Polymers 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 229920002907 Guar gum Polymers 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims 1
- 229920001202 Inulin Polymers 0.000 claims 1
- 229920000161 Locust bean gum Polymers 0.000 claims 1
- 102000002067 Protein Subunits Human genes 0.000 claims 1
- 239000004373 Pullulan Substances 0.000 claims 1
- 229920001218 Pullulan Polymers 0.000 claims 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims 1
- 229920000294 Resistant starch Polymers 0.000 claims 1
- 229920002305 Schizophyllan Polymers 0.000 claims 1
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims 1
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 claims 1
- 229940072056 alginate Drugs 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 claims 1
- 229920000615 alginic acid Polymers 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 239000007900 aqueous suspension Substances 0.000 claims 1
- 235000019312 arabinogalactan Nutrition 0.000 claims 1
- 210000001815 ascending colon Anatomy 0.000 claims 1
- 235000010418 carrageenan Nutrition 0.000 claims 1
- 229920001525 carrageenan Polymers 0.000 claims 1
- 239000000679 carrageenan Substances 0.000 claims 1
- 229940113118 carrageenan Drugs 0.000 claims 1
- 229920002301 cellulose acetate Polymers 0.000 claims 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims 1
- 229940045110 chitosan Drugs 0.000 claims 1
- 229940059329 chondroitin sulfate Drugs 0.000 claims 1
- 210000001731 descending colon Anatomy 0.000 claims 1
- 229960002086 dextran Drugs 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 235000019325 ethyl cellulose Nutrition 0.000 claims 1
- 229920001249 ethyl cellulose Polymers 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 229920000578 graft copolymer Polymers 0.000 claims 1
- 239000000665 guar gum Substances 0.000 claims 1
- 235000010417 guar gum Nutrition 0.000 claims 1
- 229960002154 guar gum Drugs 0.000 claims 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims 1
- 210000003405 ileum Anatomy 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 102000006495 integrins Human genes 0.000 claims 1
- 108010044426 integrins Proteins 0.000 claims 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims 1
- 229940029339 inulin Drugs 0.000 claims 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 claims 1
- 229960000511 lactulose Drugs 0.000 claims 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 claims 1
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 claims 1
- 235000010420 locust bean gum Nutrition 0.000 claims 1
- 239000000711 locust bean gum Substances 0.000 claims 1
- 229960003511 macrogol Drugs 0.000 claims 1
- 238000002844 melting Methods 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- 101800000857 p40 protein Proteins 0.000 claims 1
- 239000001814 pectin Substances 0.000 claims 1
- 235000010987 pectin Nutrition 0.000 claims 1
- 229920001277 pectin Polymers 0.000 claims 1
- 229960000292 pectin Drugs 0.000 claims 1
- 229920002689 polyvinyl acetate Polymers 0.000 claims 1
- 239000011118 polyvinyl acetate Substances 0.000 claims 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 235000019423 pullulan Nutrition 0.000 claims 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 235000021254 resistant starch Nutrition 0.000 claims 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 210000003384 transverse colon Anatomy 0.000 claims 1
- 125000005591 trimellitate group Chemical group 0.000 claims 1
- 229920001285 xanthan gum Polymers 0.000 claims 1
- 239000000230 xanthan gum Substances 0.000 claims 1
- 235000010493 xanthan gum Nutrition 0.000 claims 1
- 229940082509 xanthan gum Drugs 0.000 claims 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17192260.2A EP3459528B1 (en) | 2017-09-20 | 2017-09-20 | Preparation of solid dosage forms comprising antibodies by solution/suspension layering |
| EP17192260.2 | 2017-09-20 | ||
| JP2020515749A JP7204743B2 (ja) | 2017-09-20 | 2018-09-11 | 溶液／懸濁液層状化による抗体を含む固形剤形の調製 |
| PCT/EP2018/074520 WO2019057562A1 (en) | 2017-09-20 | 2018-09-11 | PREPARATION OF SOLID GALENIC SHAPES COMPRISING ANTIBODIES BY SOLUTION / SUSPENSION STRATIFICATION |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020515749A Division JP7204743B2 (ja) | 2017-09-20 | 2018-09-11 | 溶液／懸濁液層状化による抗体を含む固形剤形の調製 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023036901A JP2023036901A (ja) | 2023-03-14 |
| JP2023036901A5 true JP2023036901A5 (enExample) | 2023-04-03 |
Family
ID=59923358
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020515749A Active JP7204743B2 (ja) | 2017-09-20 | 2018-09-11 | 溶液／懸濁液層状化による抗体を含む固形剤形の調製 |
| JP2022211549A Pending JP2023036901A (ja) | 2017-09-20 | 2022-12-28 | 溶液／懸濁液層状化による抗体を含む固形剤形の調製 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020515749A Active JP7204743B2 (ja) | 2017-09-20 | 2018-09-11 | 溶液／懸濁液層状化による抗体を含む固形剤形の調製 |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US11826470B2 (enExample) |
| EP (2) | EP3459528B1 (enExample) |
| JP (2) | JP7204743B2 (enExample) |
| KR (2) | KR20200055711A (enExample) |
| CN (1) | CN111093635A (enExample) |
| AR (1) | AR112901A1 (enExample) |
| AU (2) | AU2018337493B2 (enExample) |
| BR (1) | BR112020005460A8 (enExample) |
| CA (1) | CA3075862A1 (enExample) |
| CL (1) | CL2020000735A1 (enExample) |
| CO (1) | CO2020003070A2 (enExample) |
| CR (2) | CR20210203A (enExample) |
| EA (1) | EA202090640A8 (enExample) |
| ES (1) | ES2938609T3 (enExample) |
| GE (2) | GEP20227351B (enExample) |
| IL (2) | IL272933B2 (enExample) |
| JO (1) | JOP20200064A1 (enExample) |
| MA (1) | MA50157A (enExample) |
| MX (1) | MX2020003032A (enExample) |
| MY (1) | MY209948A (enExample) |
| PH (1) | PH12020500353A1 (enExample) |
| SA (1) | SA520411573B1 (enExample) |
| SG (1) | SG11202002203YA (enExample) |
| TW (1) | TWI802592B (enExample) |
| UA (1) | UA129148C2 (enExample) |
| WO (1) | WO2019057562A1 (enExample) |
| ZA (2) | ZA202001752B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3459528B1 (en) * | 2017-09-20 | 2022-11-23 | Tillotts Pharma Ag | Preparation of solid dosage forms comprising antibodies by solution/suspension layering |
| CN112263564B (zh) * | 2020-10-30 | 2022-07-19 | 黄山中皇制药有限公司 | 一种喜炎平干混悬剂的制备方法 |
| CN112107694B (zh) * | 2020-10-30 | 2022-07-22 | 黄山中皇制药有限公司 | 一种喜炎平干混悬剂 |
| CN116236463A (zh) * | 2023-02-16 | 2023-06-09 | 山东省药学科学院 | 右酮洛芬缓释微丸胶囊及其制备方法 |
| WO2024200722A1 (en) | 2023-03-28 | 2024-10-03 | Tillotts Pharma Ag | Solid oral dosage form comprising antibodies for sustained release in the lower gastrointestinal tract |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| IT1241417B (it) | 1990-03-06 | 1994-01-14 | Vectorpharma Int | Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione |
| IT1246382B (it) | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
| GB9109645D0 (en) | 1991-05-03 | 1991-06-26 | Celltech Ltd | Recombinant antibodies |
| US5919452A (en) | 1991-03-18 | 1999-07-06 | New York University | Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies |
| CA2110899C (en) | 1991-06-21 | 2006-08-08 | Jacob G. Michael | Orally administrable therapeutic proteins and method of making |
| EP0725789B1 (en) | 1993-09-20 | 2003-03-19 | Anadis Ltd. | Method of obtaining immunoglobulins from colostrum and their use in pharmaceutical composition |
| NO309690B1 (no) | 1995-01-23 | 2001-03-12 | Western Atlas Int Inc | Detonasjonsanordning av type eksploderende brotråd for bruk med et perforeringsverktöy i en brönn |
| WO2000018500A1 (de) | 1998-09-24 | 2000-04-06 | Glatt Systemtechnik Dresden Gmbh | Einrichtung zur herstellung eines schüttfähigen produktes und verfahren zur anwendung der einrichtung |
| DE69836098T3 (de) | 1997-12-20 | 2014-04-30 | Genencor International, Inc. | In einem wirbelschichtbett hergestelltes matrixgranulat |
| US6074689A (en) | 1998-03-10 | 2000-06-13 | Immucell Corporation | Colonic delivery of protein or peptide compositions |
| FI20000780L (fi) | 2000-04-03 | 2001-10-04 | Novasso Oy | Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi |
| GB2367002A (en) | 2000-09-25 | 2002-03-27 | British Sugar Plc | Coating composition |
| GB0203421D0 (en) | 2002-02-13 | 2002-04-03 | Alizyme Therapeutics Ltd | Composition |
| US9107804B2 (en) | 2002-12-10 | 2015-08-18 | Nortec Development Associates, Inc. | Method of preparing biologically active formulations |
| ES2645930T3 (es) | 2003-01-03 | 2017-12-11 | Supernus Pharmaceuticals, Inc. | Utilización de una mezcla de dos o más materiales entéricos para regular la liberación de fármacos a través de una membrana o matriz para terapias sistémicas |
| DE10332160A1 (de) | 2003-07-15 | 2005-02-03 | Röhm GmbH & Co. KG | Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Peptid- oder Protein-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform |
| AU2004273830B2 (en) * | 2003-09-15 | 2011-03-24 | Shionogi, Inc. | Antibiotic product, use and formulation thereof |
| DE10353186A1 (de) | 2003-11-13 | 2005-06-16 | Röhm GmbH & Co. KG | Mehrschichtige Arzneiform, enthaltend eine in Bezug auf die Wirkstoffabgabe modulatorisch wirkende Substanz |
| DE10353196A1 (de) | 2003-11-13 | 2005-06-16 | Röhm GmbH & Co. KG | Mehrschichtige Arzneiform mit einer die Abgabe einer modulatorischen Substanz beeinflussenden Matrix |
| EP1755557A4 (en) | 2004-05-19 | 2007-08-29 | Glatt Air Tech Inc | GRANULES CONTAINING MICROGRANULES AND PROCESS FOR THE PREPARATION THEREOF |
| EP1863453A2 (en) | 2005-03-29 | 2007-12-12 | Evonik Röhm GmbH | Multiparticulate pharmaceutical form comprising pellets with a substance having a modular effect in relation to active ingredient release |
| CA2601339A1 (en) * | 2005-03-29 | 2006-10-05 | Roehm Gmbh | Multiparticulate pharmaceutical form comprising pellets with a matrix which influences the delivery of a modulatory substance |
| ES2424042T3 (es) | 2005-06-07 | 2013-09-26 | Esbatech - A Novartis Company Llc | Anticuerpos estables y solubles que inhiben TNF± |
| BRPI0707616A2 (pt) | 2006-02-09 | 2011-05-10 | Alba Therapuetics Corp | formulaÇÕes para um efetor de junÇço oclusiva |
| GB0607534D0 (en) | 2006-04-13 | 2006-05-24 | Univ London Pharmacy | Colonic drug delivery formulation |
| CN101677958A (zh) | 2007-03-26 | 2010-03-24 | 帝国制药株式会社 | 用于结肠-特异性递送的口服药物制剂 |
| WO2009037264A2 (en) * | 2007-09-17 | 2009-03-26 | Da Volterra | Colonic delivery of antimicrobial agents |
| CA2615137A1 (en) * | 2007-12-17 | 2009-06-17 | Pharmascience Inc. | Single layered controlled release therapeutic system |
| KR20100101106A (ko) | 2008-01-03 | 2010-09-16 | 애보트 프러덕츠 게엠베하 | 정제 미생물 리파제 과립들을 포함하는 약학 조성물 및 소화 장애들의 예방 또는 치료방법 |
| MX345039B (es) | 2008-06-25 | 2017-01-16 | Esbatech Alcon Biomed Res Unit | Anticuerpos estables y solubles que inhiben el tnfa. |
| KR101834797B1 (ko) | 2008-06-25 | 2018-03-07 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | 보편적 항체 프레임워크를 사용한 래빗 항체의 인간화 |
| CN104800147A (zh) | 2008-07-10 | 2015-07-29 | 德勒尼克斯治疗股份公司 | 用于大分子的增强的递送的方法和组合物 |
| TWI473610B (zh) * | 2008-10-28 | 2015-02-21 | Twi Biotechnology Inc | 包含雙醋瑞因（ｄｉａｃｅｒｅｉｎ）之醫藥組合物 |
| EP2340812A1 (en) | 2009-12-18 | 2011-07-06 | Ferring International Center S.A. | Granules for pharmaceutical preparations, methods and apparatus for their production |
| MX2021000431A (es) * | 2011-03-23 | 2022-10-28 | Ironshore Pharmaceuticals & Dev Inc | Metodos y composiciones para el tratamiento de trastorno por deficit de atencion. |
| EP2691415B1 (en) | 2011-03-28 | 2018-07-11 | Ablynx N.V. | Method for producing solid formulations comprising immunoglobulin single variable domains |
| WO2014142938A1 (en) | 2013-03-15 | 2014-09-18 | Aihol Corporation | Pharmaceutical formulation containing glycosaminoglycan |
| FR3022462B1 (fr) * | 2014-06-18 | 2018-04-27 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Composition orale d'anticorps anti-tnfalpha |
| IL255343B2 (en) * | 2015-05-04 | 2024-10-01 | Confluence Pharmaceuticals Llc | Sprinkle formulations of acamprosate |
| EP3459528B1 (en) * | 2017-09-20 | 2022-11-23 | Tillotts Pharma Ag | Preparation of solid dosage forms comprising antibodies by solution/suspension layering |
-
2017
- 2017-09-20 EP EP17192260.2A patent/EP3459528B1/en active Active
- 2017-09-20 ES ES17192260T patent/ES2938609T3/es active Active
-
2018
- 2018-09-11 US US16/647,322 patent/US11826470B2/en active Active
- 2018-09-11 KR KR1020207006918A patent/KR20200055711A/ko not_active Ceased
- 2018-09-11 UA UAA202002268A patent/UA129148C2/uk unknown
- 2018-09-11 GE GEAP201815318A patent/GEP20227351B/en unknown
- 2018-09-11 CR CR20210203A patent/CR20210203A/es unknown
- 2018-09-11 CN CN201880059373.2A patent/CN111093635A/zh active Pending
- 2018-09-11 MA MA050157A patent/MA50157A/fr unknown
- 2018-09-11 WO PCT/EP2018/074520 patent/WO2019057562A1/en not_active Ceased
- 2018-09-11 MY MYPI2020001378A patent/MY209948A/en unknown
- 2018-09-11 JP JP2020515749A patent/JP7204743B2/ja active Active
- 2018-09-11 SG SG11202002203YA patent/SG11202002203YA/en unknown
- 2018-09-11 GE GEAP201815611A patent/GEP20237504B/en unknown
- 2018-09-11 IL IL272933A patent/IL272933B2/en unknown
- 2018-09-11 MX MX2020003032A patent/MX2020003032A/es unknown
- 2018-09-11 JO JOP/2020/0064A patent/JOP20200064A1/ar unknown
- 2018-09-11 IL IL318231A patent/IL318231A/en unknown
- 2018-09-11 EP EP18765136.9A patent/EP3684339A1/en active Pending
- 2018-09-11 CA CA3075862A patent/CA3075862A1/en active Pending
- 2018-09-11 BR BR112020005460A patent/BR112020005460A8/pt active Search and Examination
- 2018-09-11 EA EA202090640A patent/EA202090640A8/ru unknown
- 2018-09-11 AU AU2018337493A patent/AU2018337493B2/en active Active
- 2018-09-11 CR CR20200130A patent/CR20200130A/es unknown
- 2018-09-11 KR KR1020247029638A patent/KR20240137117A/ko active Pending
- 2018-09-17 TW TW107132680A patent/TWI802592B/zh active
- 2018-09-20 AR ARP180102681A patent/AR112901A1/es unknown
-
2020
- 2020-02-18 PH PH12020500353A patent/PH12020500353A1/en unknown
- 2020-03-16 CO CONC2020/0003070A patent/CO2020003070A2/es unknown
- 2020-03-19 ZA ZA2020/01752A patent/ZA202001752B/en unknown
- 2020-03-19 SA SA520411573A patent/SA520411573B1/ar unknown
- 2020-03-20 CL CL2020000735A patent/CL2020000735A1/es unknown
-
2022
- 2022-09-30 ZA ZA2022/10822A patent/ZA202210822B/en unknown
- 2022-12-28 JP JP2022211549A patent/JP2023036901A/ja active Pending
-
2023
- 2023-11-27 US US18/520,348 patent/US20240099980A1/en active Pending
-
2024
- 2024-09-03 AU AU2024219328A patent/AU2024219328A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023036901A5 (enExample) | ||
| IL272933B2 (en) | Preparation of solid dosage forms comprising antibodies by solution/ suspension layering | |
| JP4749639B2 (ja) | 味がマスクされ、活性成分を即時放出する、被覆された顆粒の製造方法 | |
| JP4615124B2 (ja) | 制御された作用物質放出性を有する被覆された医薬品形 | |
| JP4369752B2 (ja) | プロプラノロールの時限徐放性多粒子剤型 | |
| CN1104891C (zh) | 缓释制剂 | |
| JP2005524702A5 (enExample) | ||
| JP5661281B2 (ja) | 良好な水溶解性を有する作用物質のための作用物質の制御送達を有する医薬組成物 | |
| JP2010500393A5 (enExample) | ||
| JP2002504069A (ja) | 複合エストロゲンの医薬組成物およびその使用方法 | |
| JPH0769927A (ja) | 架橋ポリマーで支持されポリマーフィルムで被覆された薬剤の制御された放出を伴なう治療組成物、及びそれらの調整方法 | |
| CN1244119A (zh) | 迅速释放和掩蔽味觉的药物剂型 | |
| CN1195984A (zh) | 含有达非那新的药物制剂 | |
| JPH05201867A (ja) | スフェロイド製剤 | |
| WO2004087175A1 (en) | Oral extended release compressed tablets of multiparticulates | |
| Swain et al. | Modified alginate beads for mucoadhesive drug delivery system: an updated review of patents | |
| JP2014518205A (ja) | 医薬品剤形又は機能性食品剤形に適したコーティング組成物 | |
| JP4234427B2 (ja) | 活性成分をベースとする微小顆粒およびその製造方法 | |
| JP2009501777A (ja) | 胃保持型製剤およびそれらの製造方法 | |
| WO2019024310A1 (zh) | 一种盐酸普拉克索缓释制剂及其制备方法 | |
| CN1972674B (zh) | 多层形式的药物 | |
| JP2005506991A (ja) | 作用物質としてペプチド又はタンパク質を含有する医薬形を製造するためのコポリマーの使用 | |
| JP2008530319A (ja) | 部分的に中和されたアニオン性（メタ）アクリラートコポリマー | |
| JP2002515423A5 (enExample) | ||
| JP2008520696A5 (enExample) |